2-aminopyrimidine derivatives for the treatment of viral infections

• US 10,647,684 B2
• Filed: 04/12/2019
• Issued: 05/12/2020
• Est. Priority Date: 02/21/2013
• Status: Active Grant

• Current Assignee: Janssen Sciences Ireland Unlimited Company (Johnson & Johnson)
• Original Assignee: Janssen Sciences Ireland Unlimited Company (Johnson & Johnson)
• Inventors: McGowan, David Craig, Raboisson, Pierre Jean-Marie Bernard, Jonckers, Tim Hugo Maria
• Primary Examiner(s): Rao, Deepak R
• Application Number:
  US16/382,816
• Publication Number:
  US 20190308940A1
• Time in Patent Office: 396 Days
• Field of Search: 544298, 514272
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C07D 239/47 One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• CPC Class Codes: C07D 239/48 Two nitrogen atoms

Abstract

This invention relates to 2-aminopyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Claims

1. A compound of formula (I)

2. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, or solvate thereof, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

3. The compound of claim 1, wherein

R₁ is hydrogen,

R₂ is (C_1-3)-alkyl, and

n=1.

4. The compound of claim 1, wherein X is S.

5. The compound of claim 1, wherein X is S═

O.

6. The compound of claim 1, wherein X is O═

S═

O.

7. The compound of claim 1, having the following structure:

8. The compound of claim 1, having the following structure:

9. The compound of claim 1, having the following structure:

10. A method of activating TLR7 and/or TLR8 to induce interferon-stimulated response elements in a subject in need thereof comprising administering to said subject at least one compound of claim 1.